Effect of benralizumab on recurrent COPD exacerbations

医学 恶化 慢性阻塞性肺病 人口 内科学 环境卫生
作者
David Singh,G J Criner,A Agusti,M Bafadhel,J Söderström,G Luporini Saraiva,Y Song,I Licaj,M Jison,U J Martin,I Psallidas
标识
DOI:10.1183/13993003.congress-2022.3906
摘要

Exacerbations of COPD (ECOPD) often cluster, with higher likelihood for a patient who has had an exacerbation to experience another. 20% of patients (pts) hospitalized for ECOPD are readmitted within 30 days (d) of discharge. In a post-hoc analysis of the benralizumab COPD trials, GALATHEA (NCT02138916) and TERRANOVA (NCT02155660), we compared recurrent ECOPD within 30 and 90d after the end of an initial event in the 100 mg (B) and placebo (PBO) arms in a selected population (≥300 eosinophils/µL, triple therapy, ≥3 prior exacerbations in the previous year who experienced ≥1 exacerbation following randomization). ECOPD was defined as symptomatic worsening for at least 3d with any of the following: use of systemic glucocorticoids, use of antibiotics, hospitalization or COPD-related death. A negative binomial model with treatment, study, region, and prior ECOPD was used. 145 pts (73 B, 72 PBO) were included with 14 (B) and 62 (PBO) recurrent ECOPD within 30d, and 48 (B) and 127 (PBO) within 90d (Table). The risk of experiencing recurrent ECOPD within 30d was reduced by 60% for moderate/severe (p=0.0022), 54% for moderate (p=0.0247), and 67% (p=0.1133) for severe exacerbations following B vs PBO. The overall pattern within 90d was similar, although lower reductions were observed. This analysis suggests that benralizumab 100 mg may reduce the risk of recurrent ECOPD within 30d and 90d.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
孟浩关注了科研通微信公众号
1秒前
晓天完成签到,获得积分10
2秒前
泽烺木完成签到,获得积分10
4秒前
落寞白曼完成签到,获得积分10
4秒前
人间不清醒完成签到,获得积分20
4秒前
欢欢发布了新的文献求助10
4秒前
快乐的奕涵完成签到,获得积分10
5秒前
zongzi12138完成签到,获得积分0
6秒前
6秒前
王哈哈完成签到,获得积分10
6秒前
香蕉觅云应助人间不清醒采纳,获得30
8秒前
11秒前
12秒前
bzdjsmw完成签到 ,获得积分10
12秒前
WebCasa应助旦皋采纳,获得10
12秒前
路易斯完成签到,获得积分10
13秒前
颜愫发布了新的文献求助10
13秒前
萌萌完成签到,获得积分10
14秒前
研友_X89o6n完成签到,获得积分10
16秒前
Ther发布了新的文献求助10
18秒前
哈哈哈完成签到,获得积分10
19秒前
21秒前
诚心的初露完成签到,获得积分10
21秒前
lyb完成签到 ,获得积分10
23秒前
风中方盒完成签到,获得积分20
23秒前
布丁圆团完成签到,获得积分10
24秒前
yikeshu完成签到,获得积分10
24秒前
Zoe完成签到 ,获得积分10
25秒前
27秒前
星辰大海应助do0采纳,获得10
28秒前
tt完成签到 ,获得积分10
29秒前
浅辰完成签到,获得积分10
30秒前
大气萤完成签到,获得积分20
31秒前
31秒前
我ppp完成签到 ,获得积分10
31秒前
32秒前
易燃物品完成签到,获得积分10
32秒前
Hello应助Ther采纳,获得10
34秒前
CherylZhao完成签到,获得积分10
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038368
求助须知:如何正确求助?哪些是违规求助? 3576068
关于积分的说明 11374313
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029